ASA404 and TNFM-NM-1 treatment in preclinical models of endocrine tumors is associated with differential TNF-R 1 and TLR- 4 M-bM-^@M-^Ssignaling

ABSTRACT: Purpose: ASA404 (Vadimezan) belongs to a class of agents with disrupting properties against tumor vasculature, which is partly mediated by TNFM-NM-1-signaling. Our aim was to investigate the potential therapeutic applicability of ASA404 against endocrine tumors. Experimental Design: We determined anti-tumoral effects in preclinical models of neuroendocrine tumors of the gastroenteropancreatic system [1] and adrenocortical cancer (NCI-H295R) by histology and immunohistochemistry. Furthermore, we characterized these models with their clearly different responsiveness regarding TNFM-NM-1 synthesis and signaling. Results: Upon treatment of tumor bearing mice significant anti-tumoral effects, an increase in TNFM-NM-1 as well as TNFM-NM-1-specific activation of downstream signaling were evident in the BON tumor model while no comparable effects were detectable for NCI-H295R. Two important modulator of TNFM-NM-1-signaling, toll-like-receptor 4 (TLR-4) and its adaptor protein LY96 were found highly expressed in BON tumors and transgenic expression in NCI-H295R partly restored TNFM-NM-1 responsiveness. Furthermore, expression of IRAK2-kinase, which has recently been linked to TLR-4-signaling as a mediator of sustained TNFM-NM-1 release was induced upon TNFM-NM-1-treatment in BON, but not in NCI-H295R cells. Finally, we identified TNFAIP3/A20, a member of an inhibitory feedback-loop downstream of both investigated signaling cascades, as overexpressed in the adrenocortical carcinoma tumor model. Subsequent analyses of clinical patient samples confirmed a correlation between tumor TNFAIP3 expression levels and overall survival in patients with ACC. Conclusions: Taken together our findings provide evidence that modulation of TNFM-NM-1-signaling could be of relevance both for the clinical course of ACC patients and as a marker of treatment response. BON or NCI-H295R tumor cells were treated in-vitro with TNFalpha and compared to unstimulated cells

ORGANISM(S): Homo sapiens

SUBMITTER: Carsten JM-CM-$ckel 

PROVIDER: E-GEOD-64250 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress